On Oct. 13, 2020, Eli Lilly announced that the government-sponsored clinical trial of its COVID-19 antibody treatment similar to one taken by U.S. President Donald Trump had been paused because of a safety concern. Lilly began its ACTIV-3 trial in August and was aiming to recruit 10,000 patients primarily in the U.S.